Monthly Archives: April 2026

600,000 New Wegovy® Pill Prescriptions Written in First Two Months

KELOWNA, BC / ACCESS Newswire / April 21, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides this update of additional recent developments in the fast-moving glucagon-like peptide-1 ("GLP-1") oral (or "pill") market.

The GLP-1 oral pill sector is growing much faster in 2026 than expected, and faster than the pre-existing GLP-1 injectable sector. The industry's first-ever GLP-1 pill for weight loss, Wegovy^®, was approved by the US Food and Drug Administration ("FDA") on December 22, 2025 and launched in the US in January 2026. Prior to that, Rybelsus^® was the only FDA approved GLP-1 drug available in pill form, but it was approved for diabetes control and only used secondarily (or, "off label") for weight loss.

Within less than the first two months of its launch, Novo Nordisk^® had disclosed that over 600,000 prescriptions for the Wegovy^® pill had been written, and will report on its first-quarter sales including the Wegovy^® pill in May. Both the Wegovy^® injectable and the Wegovy^® pill contain the same active drug: semaglutide, with which Lexaria has conducted extensive testing to determine compatibility with Lexaria's DehydraTECH^™ technology.

According to Global Data Healthcare, 51% of the growth in Wegovy^® revenue between 2026 and 2031 is expected to come from the pill format, with injectable semaglutide expected to reach peak revenue in 2030, when Novo Nordisk's Wegovy^® semaglutide franchise is expected to reach $15.9 billion in annual revenue. This will be quite an achievement since 2025 semaglutide revenue derived from Wegovy^® was 100% in the injectable category, whereas 2031 revenue from Wegovy^® products is expected to be 17% from pills.

As Lexaria's press release of March 24 noted, TD Cowen^® raised their previous 2030 sales forecast of the overall GLP-1 sector from $101 billion to $139 billion, Roots Analysis is forecasting sales of $180 billion by 2035, while UBS Investment Bank^® expects 2029 GLP-1 sales to reach $126 billion.

It is not possible to know in advance, what overall portion of the GLP-1 market will be captured by the oral pill format vs. the traditional injectable format; but, if the Wegovy^® based semaglutide revenue projections are any indication, it could certainly be 17% or higher within a few short years of product launch. In fact, according to a Novo Nordisk^® executive, oral GLP-1 drugs may account for as much as 33% of the broader GLP-1 market by that time. Based on the various GLP-1 revenue forecasts ranging from $101 billion to $180 billion, this could imply an oral pill sector ranging in size from $17 billion to $60 billion by the mid 2030's.

This oral pill GLP-1 market is the specific market sector that Lexaria's technology is focused on. As noted within an article appearing on CNBC, "Novo Nordisk's new Wegovy^® GLP-1 pill appears to be expanding the obesity treatment market, drawing in new patients rather than converting existing ones from injections." If this proves to be a sustainable trend, then a successful GLP-1 pill sector could power the broader GLP-1 market to become even larger than original projections and provide enhanced opportunities for Lexaria's DehydraTECH^™.

The onset of GLP-1 drugs has radically changed the diabetes and weight-loss market sectors. The more recent onset of the GLP-1 oral pill sector is now driving revenues faster and further than injectable GLP-1 drugs alone. Lexaria's DehydraTECH^™ has demonstrated performance enhancing abilities across three prominent GLP-1 drugs: semaglutide, tirzepatide and liraglutide; and Lexaria's announced 2026 Research & Development program intends to explore DehydraTECH's possible expanded applicability to next generation GLP-1 drugs including, but not limited to, retatrutide and amycretin. Lexaria remains in discussions with pharmaceutical companies related to their potential interest in DehydraTECH^™ for their oral GLP-1 strategies.

About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH^™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

INVESTOR CONTACT:

George Jurcic - Head of Investor Relations
[email protected]
Phone: 250-765-6424, ext 202

SOURCE: Lexaria Bioscience Corp.

Contracts signed for Animal Study GLP-1-A26-1

KELOWNA, BC / ACCESS Newswire / April 15, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce the engagement of the contract research organization ("CRO") to execute and report on its 2026 animal Study #1 (GLP-1-A26-1) that will evaluate a number of formulation enhancements using both DehydraTECH-semaglutide ("DHT-sema") glucagon-like peptide-1 ("GLP-1") compositions and DehydraTECH-CBD ("DHT-CBD") compositions to explore the potential for additional improved performance as well as stake new intellectual property ("IP") claims (the "Study").

Contracts with the CRO have been signed, materials sourcing is underway, and Study design is being finalized with the goal of beginning dosing within approximately 60 days.

"The global arms race in diabetes control, weight loss and other GLP-1-indicated areas of treatment is intensifying with recent new oral drugs being approved by the Food and Drug Administration ("FDA")," said Richard Christoper, CEO of Lexaria Bioscience. "With tens of billions of dollars in new annual revenue soon expected in the sector, there has never been a better time to stake new legal IP claims in order to offer the pharmaceutical industry improved performance including reducing side effects, while improving Lexaria's probabilities of becoming an indispensable provider of improved drug delivery technology."

While final design parameters of this Study are ongoing, it is expected to utilize Sprague-Dawley rats with 8 to 11 separate arms evaluating a number of different novel compositions. Blood samples will be taken at multiple timepoints through an 8-24-hour post-dosing period to quantify the pharmacokinetic performance of each composition. In addition, the Study will also measure drug concentrations in the brain since DehydraTECH has, in the past, evidenced apparent superior absorption of active ingredients into brain tissue, an area of intense interest due to the fact that GLP-1 drug performance is increasingly understood to include or even depend upon involvement of brain neurochemistry, thus making brain biodistribution vital. There will be one reference arm using an existing DHT-sema composition and another reference arm using an existing DHT-CBD composition. Lexaria intends to leverage the wealth of study data that we have amassed from previous work by utilizing our proprietary historical data and the reference arms as baseline comparators to the current Study results as we search for areas of superiority.

One of the novel objectives of this Study will be to evaluate alternative/additive formulations to SNAC (salcaprozate sodium) which is currently in use by Novo Nordisk® with their oral Rybelsus® and Wegovy® tablet products. If Lexaria is able to establish novel new formulations with superiority to SNAC, we may be able to register new patents and create valuable new proprietary IP and an industry alternative to SNAC that could be of interest within the keenly competitive GLP-1 sector.

Lexaria will update its stakeholders once dosing has begun. The Study is fully funded from existing corporate resources.

About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

INVESTOR CONTACT:

George Jurcic - Head of Investor Relations
[email protected]
Phone: 250-765-6424, ext 202

SOURCE: Lexaria Bioscience Corp.

The number of oral weight-loss / diabetes drug treatments is expanding, increasing demand for the reduction of side effects

KELOWNA, BC / ACCESS Newswire / April 7, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to recognize that the US Food and Drug Administration ("FDA") has approved Eli Lilly and Company's^® Foundayo^™ glucagon-like peptide-1 ("GLP-1") agonist (orforglipron) oral tablet for adult use in controlling obesity and weight-related medical conditions.

"This latest approval from the FDA expands choices for Americans searching for the right weight control drug that best suits their needs," said Richard Christopher, CEO of Lexaria Bioscience Corp. "Expanded choices within the historically limited oral weight-loss drug category increases opportunities for Lexaria to partner with the leading companies in the pharmaceutical industry to implement DehydraTECH^™ technology to improve patient experiences including through the potential for reduced side effects."

The recent FDA approval of Foundayo^™ follows both the December 2025 approval of Wegovy^® tablets for weight loss and the September 2019 approval of Rybelsus® tablets for diabetes, bringing the total number of FDA approved GLP-1 oral brand offerings to 3. In 2025, worldwide revenues of the sole oral offering within the GLP-1 category (Rybelsus^®) totaled $3.5B. This represented less than 5% of the 2025 worldwide GLP-1 revenue total, highlighting the tremendous upside growth potential that oral options have within the GLP-1 marketplace.

As Lexaria recently announced, its forward-looking strategic plans for the GLP-1 sector continue to be centered around improving the patient experience while using these drugs for indications including but not limited to diabetes and weight loss, primarily through the reduction of unwanted side effects.

In Eli Lilly's clinical trial, patients taking Foundayo^™ (orforglipron) for the full study duration of 72-weeks lost an average of 27.3 pounds (12.4%). One of Foundayo's™ biggest advantages over Novo Nordisk's existing Wegovy^™ (semaglutide) oral medication is that Foundayo^™ can be taken at any time of day regardless of eating habits, whereas Wegovy™ tablets must be taken only on an empty stomach 30 minutes before breakfast. Notwithstanding this and as reported by Scientific American^®, "Orforglipron showed higher rates of adverse side effects such as nausea, vomiting and other gastrointestinal issues compared with semaglutide. More people discontinued orforglipron during the trial than those who stopped taking semaglutide, too".

According to Eli Lilly, "The most common side effects of Foundayo^™ include nausea, constipation, diarrhea, vomiting, indigestion, stomach (abdominal) pain, headache, swollen belly, feeling tired, belching, heartburn, gas, and hair loss. These are not all the possible side effects of Foundayo."

In various studies performed during the past ~2 years, DehydraTECH has already been evaluated orally with semaglutide, liraglutide, and tirzepatide and has successfully reduced side effects with each drug. For example, in Study GLP-1-H24-4, Lexaria reported a 47.9% reduction in the total quantity of adverse events derived from oral DehydraTECH-semaglutide vs. Rybelsus^™.

Lexaria has also announced plans to conduct DehyrdaTECH-processed GLP-1 testing in 2026 with additional GLP-1 drugs not previously evaluated, including retatrutide and amycretin, and is considering testing DehydraTECH-processed orforglipron as well. Lexaria believes that reducing adverse events in the GLP-1 drug sector is a significant competitive advantage enjoyed by DehydraTECH technology, which is now backed by 65 issued patents around the world.

About Lexaria Bioscience Corp. & DehydraTECH

DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

INVESTOR CONTACT:

George Jurcic - Head of Investor Relations
[email protected]
Phone: 250-765-6424, ext 202

SOURCE: Lexaria Bioscience Corp.

Contracts signed for Human Pilot Study #7 (GLP-1-H26-7)

KELOWNA, BC / ACCESS Newswire / April 1, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the engagement of the contract research organization ("CRO") to execute and report on its Human Pilot Study #7 (GLP-1-H26-7) that will evaluate 2 oral DehydraTECH-semaglutide ("DHT-sema") compositions against commercially available Wegovy^® tablets (the "Study").

Contracts with the CRO have been signed and submissions are currently being prepared to obtain the required ethics approval from an independent review board.

Study design is virtually complete and is expected to be a 5-week parallel group design, investigating 3 separate arms to assess safety & tolerability and pharmacokinetic ("PK") properties that will compare salcaprozate sodium ("SNAC")-inclusive DHT-sema tablet and capsule formulations to commercially available Wegovy^® tablets, under fasted pre-dose conditions. Lexaria hopes to preserve the superior safety & tolerability profiles as evidenced in previous Lexaria GLP-1 studies such as GLP-1-H25-4, combined with PK performance that matches or exceeds that of the commercial oral tablet brands Ryblesus^® and Wegovy^®.

If successful, the Study results will be additive to an already impressive data set aimed at generating interest from pharmaceutical partners seeking to enter into commercial relationships encompassing Lexaria's proprietary DehydraTECH technology.

What's New?

This Study explores several new DehydraTECH enhancements not previously evaluated, which include but are not limited to the following 2 main improvements:

(1) First, an oral tablet DHT-sema composition is being used by Lexaria for the first time, as opposed to the capsule compositions included in all our previous DHT glucagon-like peptide-1 ("GLP-1") studies. Novo Nordisk's^® Rybelsus^® and Wegovy^® oral semaglutide medications both use specially formulated tablets designed to temporarily adhere to the stomach lining and disintegrate and dissolve releasing agents in a focal manner that aids in optimizing absorption of the active ingredient - semaglutide - into the human body. For the first time ever, Lexaria has attempted to mimic certain properties of this Rybelsus^®/Wegovy^® tablet delivery modality into its DHT-sema tablets.

(2) Second, both the Lexaria DHT-sema tablet and capsule test articles will be formulated with SNAC, which will be the first time these formulations are evaluated over a multi-dose, multi-week time period in humans. The 5-week duration of the Study is expected to be long enough to reach so-called steady-state, which is when drug concentrations in the body reach a constant concentration. Earlier DHT-sema human pilot studies that Lexaria conducted in 2024 and 2025 that also used SNAC (but did not use tablets), were limited by single-dose study designs; therefore, of much shorter duration. Novo Nordisk's branded Rybelsus^® and Wegovy^® semaglutide based products are both formulated with SNAC.

Lexaria will update its stakeholders once the ethics board approval for the Study has been achieved, at which time patient recruitment can begin. The Study is fully funded from existing corporate resources.

About Lexaria Bioscience Corp. & DehydraTECH

DehydraTECH^™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

INVESTOR CONTACT:

George Jurcic - Head of Investor Relations
[email protected]
Phone: 250-765-6424, ext 202

SOURCE: Lexaria Bioscience Corp.